Senesco to Present Abstracts at International Cytokine Society Meeting.

NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) announced today its researchers will present two abstracts at the joint meeting of the International Cytokine Society and the International Society for Interferon and Cytokine Research, which will be held in San Juan, Puerto Rico, from October 21-25, 2004. The topic of this year's meeting is "Cytokines in Cancer and Immunity." The abstracts are titled:

1) "The Reduction of TNF-alpha Secretion by siRNA Against Eukaryotic Translation Initiation Factor 5A in PBMCS."

2) "Eukaryotic Translation Initiation Factor 5A Regulates Interferon Gamma-Stimulated NF-KB Activation and Cytokine Secretion in HT-29."

Dr. John E. Thompson, the Company's Executive Vice President and Chief Scientific Officer, commented, "As we continue to elucidate the function of Factor 5A, we are pleased that the data presented in these abstracts supports our contention that Senesco's gene technology plays an important role in immune response via cytokine activation."

About Senesco Technologies, Inc.

Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has begun to explore ways to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as Alzheimer's, glaucoma, ischemia and arthritis, among others. Senesco partners with leading-edge companies and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, New Jersey, and utilizes research laboratories at the University of Waterloo in Ontario, Canada, and the University of Colorado in Denver, Colorado, as well as other institutions.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the successful conversion of the Company's letter of intent into a license agreement; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.